Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB-302
- Development stage
- Preclinical
- Lead developer
- Therabest
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
TB-302 is an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy engineered with a chimeric antigen receptor (CAR) targeting the disialoganglioside GD2. Developed by Therabest using its proprietary EiNK (Enhanced iPSC-derived NK) platform, TB-302 is designed as an "off-the-shelf" immunotherapy for the treatment of glioblastoma. The CAR-NK cells are engineered to specifically recognize GD2, a surface antigen highly expressed on neuroectodermal tumors including glioblastoma, while sparing most normal tissues. Upon binding to GD2-expressing tumor cells, the NK cells are activated to induce targeted cell-mediated cytotoxicity. This approach aims to provide a scalable and standardized alternative to patient-derived cell therapies, overcoming limitations such as donor variability and limited production capacity.
- Other names
- EiNK αGD2 CAREiNK-GD2EiNK-GD-2EiNK-GD 2
02
Targets
GD2
Beyond the preview
Go deeper on TB-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB-302.